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Abstract
Background: Quantification of T-cell receptor (TCR) chain families can be utilized for detection
of clonal T-cell populations. Besides southern blotting and antibody-based approaches, quantitative
real time PCR (qRT PCR) has been more widely applied in this context during the last years. Here,
the heterogeneity of sequences within single families is the most challenging problem for exact
quantification.
Method: Vβ-families were quantified using a universal reverse primer and family-specific forward
primers with TaqMan technology on a light cycler instrument. Relative concentrations were
calculated considering slopes and crossing points of each PCR reaction. Total expression of α/β
TCR was assessed by quantification of the constant α-chain as a further control.
Results: The method was tested by serial dilutions of clonal T-cells in mononuclear cells from
healthy volunteers. Calculated percentages were in good correspondence with qRT PCR results
demonstrating high reliability. Duplicates showed excellent technical reproducibility. We analyzed
blood samples of 20 healthy volunteers for determination of mean and standard deviation for each
family. The method was applied both to tissue and blood samples from patients with carcinomas
and hematological disorders.
Conclusion: We introduce a versatile method for the relative quantification of Vβ-families by real
time PCR. The experimental strategy described allows the identification of alterations in the Vβ-
family repertoire.
Background
T-lymphocytes are specialized mediators of the adaptive
immune system, selectively destroying cells altered by
viral infection or malignant transformation [1,2]. T-cell
mediated immune responses are characterized by activa-
tion and subsequent clonal expansion of antigen-specific
cells. Recognition of Major Histocompatibility Complex
class I (MHC-I) bound peptide is mediated by the dimeric
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transmembrane T-cell receptor (TCR) composed of an α-
and a β-chain in the majority of cases. The high diversity
of these chains is generated by stepwise recombinations of
a multitude of variable (V), in case of the β-chain diversity
(D), and joining (J) gene sequences with a corresponding
constant (C) chain during thymic T-cell evolution [3]. V-
genes are grouped in families consisting of genes with at
least 50% sequence homology [4].
T lymphocyte repertoire alterations can be evaluated by
TCR-diversity restriction analyses of the sequence or the
length of the high variable part of the α- or β-chains (e. g.
spectrotype, SSCP ('single strand conformation polymor-
phism'), DGGE ('denaturing gradient gel electrophore-
sis'), heteroduplex analysis [5-11]) or by TCR V-family
quantification [12-16]. Because of the lower described
number of Vβ-families compared to Vα-families, the
higher variability of the β-chain, and the fact that each T-
cell clone can express two different α-chains but only one
β-chain, the Vβ-chain has been largely preferred for this
type of analysis [12,13,17,18].
Quantification of Vβ-families have been investigated by
means of different approaches as southern blotting or,
more recently, Fluorescence Activated Cell Sorter (FACS)
and quantitative real time reverse transcribed PCR (qRT
PCR) [5,12-14]. In contrast to other approaches, PCR-
based methods could detect a higher number of different
families, had higher selectivity, and were applicable to dif-
ferent specimens. A cumbersome limitation for qRT PCR
assessments was the suboptimal establishment of stand-
ard dilution curves for exact quantification due to the high
heterogeneity of sequences within each family.
Here we introduce a versatile and rapid method for qRT
PCR relative quantification of Vβ-family expressions
based on slope and crossing point of the respective PCR
reaction overwhelming therefore the problem of estab-
lishing standard dilution curves.
Methods
Specimen collection
Peripheral blood samples were drawn form patients and
healthy volunteers. Tissue samples were collected from
patients with colorectal cancer who underwent therapeu-
tical resection. Both patients and controls had given
informed consent for the use of their specimens before
sampling. Human T acute lymphoblastic leukemia (ALL)
cell lines JURKAT, MOLT-16, and CCRF-CEM were pur-
chased from German Collection of Microorganisms and
Cell Cultures (DSMZ) and cultivated under recom-
mended conditions.
RNA extraction and cDNA synthesis
Total RNA was extracted from peripheral blood mononu-
clear cells (PBMCs) or fresh tissue using TRIzol® (Invitro-
gen, Carlsbad, California, USA) or RNeasy®  Mini Kit
(Qiagen, Hilden, Nordrhein-Westfalen, Germany)
according to manufacturers' instructions. RNA was quan-
tified using a NanoDrop® ND-1000 spectrophotometer
(Thermo Fisher Scientific, Wilmington, Delaware, USA),
and integrity was checked electrophoretically. Reverse
transcription was performed with Omniscript Reverse
Transcriptase®  (Qiagen) as described previously [19].
Samples were stored at -20°C.
Relative quantification of Vβ-families
For estimation of the relative expression of a single TCR
Vβ-chain, qRT PCRs were performed with a universal
reverse primer HBC-rev, a TaqMan probe HBCTP-FAM,
both annealing at the constant part of the β-chain (Cβ),
and Vβ-family-specific forward primers (modified from
[10], Table 1, Figure 1A). Nomenclature of Vβ-primers
corresponded to the classification of Arden et al [4]. A
Mastermix of 19 μl for each of the 29 reactions (LightCy-
cler TaqMan Master®, Roche, Basel, Switzerland) contain-
ing 0.5 μM reverse primer HBC-rev, 0.1 μM TaqMan-
probe HBCTP-FAM, and 2 μl template cDNA was pre-
pared. For Vβ-family specific amplification, the corre-
sponding forward primer was added to a final
concentration of 0.5 μM. A negative control without for-
ward primer was added. Amplification was performed
after an initial denaturation step of 95°C for 1 min in 45
cycles of 95°C for 10 sec, 60°C for 30 sec, and 72°C for 1
sec with data aquisition. The cycling was followed by a ter-
minal elongation step at 72°C for 2 min. Crossing points
were determined using the Fitpoint algorithm as imple-
mented in LightCycler software 3.0. Slope of each family
specific reaction was determined by linear regression ana-
lyzing a dilution series (1, 0.1, and 0.01) of a cDNA mix-
ture of diagnostic samples. The average of these slopes 
was used for determination of c' as described below.
For the calculation of the percentage P of each Vβ-family
j, it was assumed that the effective concentration c of each
marker was
where Cp was the Crossing point,  [ΔCp/log(c)] was the
mean slope, and a was considered as an unknown con-
stant for normalization. Defining a linear concentration
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Table 1: Primers/probe for quantification of Vβ-families (modified from [10], TaqMan).
Primer Sequence (5' – 3')
HBV1.1 CAC TCT GAA CTA AAC CTG A
HBV2 TCA ACC ATG CAA GCC TGA CC
HBV3 CGC TTC TCC CTG ATT CTG GAG TCC
HBV4 TTC CCA TCA GCC GCC CAA ACC TA
HBV5A CTG AGA TGA ATG TGA GCA CCT TG
HBV5B CTG AGC TGA ATG TGA ACG CCT TG
HBV6A AGA TCC AGC GCA CAG AGC G
HBV6B AGA TCC AGC GCA CAS AGC A
HBV7 GCC AAG TCG CTT CTC ACC TG
HBV8 TGA AGA TCC AGC CCT CAG AAC CC
HBV9 TCT CAC CTA AAT CTC CAG ACA AAG
HBV10 CCA CGG AGT CAG GGG ACA CA
HBV11 TGC CAG GCC CTC ACA TAC CTC TCA
HBV12A GAG AAT TTC CTC CTC ACT CTG G
HBV12B GAC CTC CCC CTC ACT CTG G
HBV13A CTC AGG CTG CTG TCG GCT G
HBV13B CTC AGG CTG GAG TTG GCT G
HBV14 AGG GTA CAA AGT CTC TCG AAA AG
HBV15 CAG GCA CAG GCT AAA TTC TCC
HBV16 GAA CTG GAG GAT TCT GGA GT
HBV17 GAA GGG TAC AGC GTC TCT CGG
HBV18 TTT CTG CTG AAT TTC CCA AAG AGG
HBV19 TCT CAA TGC CCC AAG AAC GCA C
HBV20 AGG TGC CCC AGA ATC TCT CAG
HBV21 TCA AAG GAG TAG ACT CCA CTC TC
HBV22 AGA TCC GGT CCA CAA AGC TG
HBV23 ATT CTG AAC TGA ACA TGA GCT CCT
HBV24 ATC CAG GAG GCC GAA CAC TTC
HBCTP-FAM FAM-ATG GCT CAA ACA CAG CGA CCT CGG-TAMRA
HBC-rev GGT GTG GGA GAT CTC TGC TTC
FAM: 6-carboxyfluorescin; TAMRA: 6-carboxytetramethylrhodamine, S: C or G
Primers and probe annealing sites and Vβ-families distribution in peripheral blood of healthy volunteers Figure 1
Primers and probe annealing sites and Vβ-families distribution in peripheral blood of healthy volunteers. (A) 
Structure of the β-chain and annealing sites of primers and of the TaqMan probe. Forward primers (HBV) anneal at the variable 
region, reverse primer (HBC) and TaqMan probe anneal at the constant region (B) Average percentages and standard devia-
tions for Vβ-families in PBMCs obtained from 20 healthy controls. Family percentages Pj [%] reflecting single family expression 
by the sum of all measured Vβ-families are shown.
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equivalent ,  the  percentage  P [%] of a Vβ-
family j equaled
assuming a constant s for all families.
Quantification of TCR constant α-chain
For determination of total TCR expression, the TCR con-
stant  α-chain (HAC) was quantified on a LightCycler®
(Roche) as well as the low-abundance housekeeping gene
porphobilinogen deaminidase (PBGD) for normalization
as described [19]. PCR reactions were optimized using a
mixture of cDNA as template. For quantification, LightCy-
cler® FastStart DNA Master HybProbe (Roche) was used.
Primer sequences, final MgCl2 concentration, and anneal-
ing temperatures TA were listed in Table 2. After optimiza-
tion of PCR conditions, fragments were amplified
conventionally, cloned into a pCR2.1-TOPO vector, and
transformed into TOPO10' competent E. coli using TOPO
TA Cloning® Kit (Invitrogen). After subcloning in liquid
ImMedia®  (Invitrogen) and plasmid preparation with
QiaMiniprep®  Kit (Qiagen), clones were linearized by
digesting with EcoR I (Fermentas, St. Leon-Rot, Baden-
Württemberg, Germany). Clones were sequenced, quanti-
fied spectrophotometrically and serially diluted as con-
centration standards. Sample concentrations were
extrapolated plotting sample-crossing point Cp against the
regression line through standard-Cp. RNA quantity was
expressed as ratio plasmid equivalent HAC to PBGD.
Results and Discussion
Slopes of the PCR reactions for all Vβ-families were deter-
mined by dilution series of a positive control as described
(data not shown). The average slope was 3.966 with a
standard deviation of 0.61. This value was used for the cal-
culation of family percentages. For assessment of mean
value and standard deviation of each family in peripheral
blood, PBMCs of 20 healthy volunteers were analyzed
(Figure 1B).
For assessment of reliability and reproducibility, samples
containing 105 PBMCs of three healthy controls were pre-
pared and different amounts of JURKAT-cells were added.
JURKAT is a TCR α/β-expressing T-ALL cell line. Using
serial dilution, aliquots of 50, 500, 5000, and 50,000 JUR-
KAT cells were produced and subsequently added to
PBMCs. Sample preparation, RNA extraction, cDNA syn-
thesis, and qRT PCR were performed in duplicates for all
concentrations for each volunteer. Results were expressed
as averages of the calculated percentages of the sample
duplicates. The mean difference in the percentage of each
Vβ-family in all dilution duplicates was 1.01% indicating
excellent technical reproducibility. For all three healthy
control PBMCs spiked with JURKAT cells, a clear increase
in percentage value of Vβ-family 8 was observed compar-
ing 5000 to 500 cells per 105 PBMC (Figure 2A). Assuming
70% of mononuclear cells in peripheral blood expressing
β-chains and 5.88% of the tested PBMCs belonging to Vβ8
(average percentage from 20 healthy controls), we calcu-
lated the theoretical percentages of family 8 dependent of
the amounts of JURKAT cells added, which were in good
correspondence with the mean of the measured values
from the three healthy controls as shown in Figure 2B. As
further validation, cell line MOLT-16 and CCRF-CEM
were spiked in PBMCs of volunteer 2 as described above
(Figure 3). Percentages of families not expressed by the
cell lines relatively decreased at higher amounts of spiked
cells. MOLT-16 weakly expressed a second Vβ-family,
which became apparent at 5000 MOLT-16 cells per 105
PBMCs.
Because total amount of TCR α/β expression could be dif-
ferent among various types of specimens, we quantified
the constant α-chain as a control of sample quality. HAC
expression was 50-fold higher in PBMCs than in tissue
samples (data not shown).
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Table 2: Primers/probes sets for quantification of PBGD and Cα-chain (FRET).
Primer/probe Sequence (5'-3') TA MgCl2
(mM)
Standard 
dilutions (pg/μl)
PBGD-fwd TGC AGG CTA CCA TCC ATG TCC CTG C 65°C 4 1/0.1/0.001
PBGD rev AGC TGC CGT GCA ACA TCC AGG ATG T
PBGD-3Fl CGT GGA ATG TTA CGA GCA GCA GTG ATG CCT ACC-Fl
PBGD-5LC LC-TGT GGG TCA TCC TCA GGG CCA TCT TC-ph
HAC2-fwd ACA CCT TCT TCC CCA G 60°C 3 10/1/0.01
HAC2-rev TCC AGT TGG TGG CAT T
HAC2-3Fl GTG ATT GGG TTC CGA ATC CTC C-Fl
HAC2-5LC LC-CTG AAA GTG GCC GGG TTT AAT CT-ph
TA: Annealing temparature; Fl: Fluorescine; LC: LC Red 640; ph: phosphateJournal of Translational Medicine 2008, 6:34 http://www.translational-medicine.com/content/6/1/34
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In this study, we introduced a new approach for estimat-
ing the distribution of Vβ-family expression in a popula-
tion of T-cells. To determine the effective concentration of
a transcript, standard dilutions of the specific fragment are
generally utilized. In case of Vβ-family analysis, not a sin-
gle target but a big amount of different close related tran-
scripts has to be quantified because of the high variability
of the Complement Determining Region 3 (CDR3) both
in length and sequence. Therefore, establishment of a PCR
in which a dilution series of a single amplicon (standard
curve) is used for normalization, besides increase in costs,
can not lead to exact results even using probes annealing
to the constant part of the Vβ-chain. As PCR reactions lead
to an exponential increase of produced fragments, and as
a result crossing point values have to be interpreted loga-
rithmically concerning the effective concentration of the
target, it is possible to calculate percentages without nor-
malization and independently from the sample concen-
tration when crossing points and slope are taken into
consideration. For these reasons, in order to by-pass
CDR3 diversity, we established a system in which relative
quantification is based on the comparison of crossing
points, rather than performing a family-by-family quanti-
fication using single sequence plasmids for normaliza-
tion.
There are two drawbacks on the approach: First, because
the system is ,normalized' by the sum of its c'-values,
results from runs with more than three lacking crossing
points (because of suboptimal sample quality or technical
problems) will not be informative. Second, the high
standard deviation of the slopes limits the correctness of
the mathematical procedure. Exemplary calculations
showed that this effect was of no practical relevance as
long as the concentration difference between compared
samples, reflected by the difference between the sums of
all  c'  (c'total), did not exceed a factor of 100 (data not
shown). Nevertheless, this effect may play a role compar-
ing blood with tissue as HAC/PBGD ratio in tissue is
lower than in PBMCs. If the difference would be much
higher, mathematical corrections of the percentage of a
single predominant family should be performed consider-
ing Δc'total and sj.
The method was applied to blood samples of patients
with hematological diseases and to colon carcinoma tis-
sues. Three examples with representative Vβ patterns were
shown in Figure 4. Pattern A showed the T-cell family rep-
ertoire of a patient affected by T prolymphocytic leukemia
with 98.0 leukocytes per nl and 89% CD4/CD8 positive
cells (FACS analysis, data not shown) in peripheral blood.
The pathological clone expressed Vβ-family 17 and repre-
sented more than 98% of all TCR α/β  positive lym-
phocytes in peripheral blood. Pattern B showed a patient
with suspected T-/NK-LGL lymphoproliferation. Vβ-fami-
lies 6b, 22, and 24 exceeded mean plus two standard devi-
ations as determined in twenty healthy controls.
Therefore, a monoclonal TCR α/β expressing lymphopro-
liferation was unlikely and findings had to be interpreted
as reactive T cell expansion. Pattern C showed the Vβ fam-
ily distribution in a representative colon carcinoma tissue
sample. A higher percentage of Vβ-family 14 compared to
other families was observed. If TCR restriction in the
tumor compartment reflects a spontaneous expansion of
tumor-specific T-cell clones is still matter of debate.
Compared to techniques characterizing the CDR3 region
(e.g. spectrotyping, SSCP, DGGE), the method described
is less time-consuming and useful for high-throughput
screening analyses. As for spectrotyping, conclusive proof
Serial dilutions of JURKAT cells expressing Vβ-family 8  spiked in PBMCs of three healthy volunteers Figure 2
Serial dilutions of JURKAT cells expressing Vβ-family 
8 spiked in PBMCs of three healthy volunteers. (A) 
measured percentages of family 8 in case of 50, 500, 5000, 50 
000 JURKAT cells added to 100 000 PBMCs; (B) mean per-
centages of the three volunteers compared with theoretical 
values calculated assuming 5.88% family 8 without JURKAT 
cells and 70% TCR α/β positive cells in 100 000 PBMCs. Pj: 
Vβ-chain relative expression.
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of clonality can only be achieved by sequencing.
Approaches like TC landscape combine CDR3 length
analysis with Vβ-family quantification by FACS quantifi-
cation in order to improve sensitivity [5]. Due to higher
number of detectable families and higher sensitivity, the
use of a high-throughput PCR-based quantification algo-
rithm could make a combined approach even more effec-
tive [16].
Conclusion
We present a novel and versatile approach for high-
throughput  Vβ  family quantification. Our approach is
suitable for samples from blood or bone marrow as well
as from tissue. Because of high reproducibility, compara-
tive analyses of samples in different time points or from
different compartments are possible.
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Serial dilutions of CCRF-CEM (Vβ9) and MOLT-16 (Vβ2, Vβ18) cell lines in PBMCs of a healthy volunteer. 
Measured percentages of all families in case of 50, 500, 5000, 50 000 CCRF-CEM cells (A) or MOLT-16 cells (B) added to 100 
000 PBMCs of volunteer 2. Dilutions, RNA extraction, cDNA synthesis and qRT PCR are performed in duplicated. Mean per-
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Relative quantification of TCR-Vβ-families: Examples of clinical samples Figure 4
Relative quantification of TCR-Vβ-families: Examples of clinical samples. (A) T prolymphocytic leukemia, (B) sus-
pected T/NK-LGL lymphoproliferation, (C) Colon carcinoma tissue. Peripheral blood Vβ-chain values (A, B) exceeding mean 
plus two standard deviations in healthy controls are marked with asterisk. Pj: Vβ-chain relative expression.
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